Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In an open-label, 6-month, European Phase II trial, IDEV's octreotide implant maintained GH levels at <5
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury